Comparing the current results to its competitors, Biorestorative Therapies Inc reported Revenue increase in the 1 quarter 2026 by 14.6 % year on year. The sales growth was above Biorestorative Therapies Inc 's competitors' average revenue growth of 7.16 %, achieved in the same quarter.
Biorestorative Therapies Inc , slower than the average decrease reported by the company's competitors of -4.91 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -4.91 %
Biorestorative Therapies Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes pharmaceutical, biotechnology, and medical device firms, as well as private and public stem cell companies engaged in cell-based medical technologies and therapies. The field of regenerative medicine is advancing rapidly, with a focus on cell-based therapies derived from various cell sources. Competition in the obesity market has intensified, particularly with products such as Ozempic and Wegovy (semaglutide), including the anticipated launch of FDA-approved oral Wegovy in January 2026. Competitors typically possess significantly greater financial, technological, research and development, marketing, and personnel resources. Additionally, the Biologics Price Competition and Innovation Act (BPCIA) establishes an abbreviated approval pathway for biosimilar and interchangeable biological products, which may be utilized by future competitors of the company's FDA-approved biologic product candidates.
Publicly Traded Peers of Biorestorative Therapies Inc
Altimmune inc Share Performance
-6.13%
This Year
Altimmune inc
Profile
Altimmune Inc's business model is focused on developing and commercializing innovative immunotherapies for treating infectious diseases and improving immune responses.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Sources:
Biorestorative Therapies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biorestorative Therapies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
